Correlia Biosystems has filed a notice of an exempt offering of securities to raise $3,250,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Correlia Biosystems is raising $3,250,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Akwasi Apori played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Correlia Biosystems
Correlia Biosystems is a UC Berkeley spinoff company based out of the QB3@953 startup incubator in San Francisco. Correlia develops innovative microscale tools that accelerate the rate of molecular interactions for rapid measurements of biomolecules. Our versatile SimpleScan technology opens up new biological questions from less than two microliters of sample, with rapid results that allow for dynamic monitoring of protein expression profiles (rather than simple end-point measurement). Applications range from enabling next-gen proteomic data sets to point-of-care diagnostics.
To learn more about Correlia Biosystems, visit http://correliabio.com/
Contact:
Akwasi Apori, Chief Executive Officer
510-859-4577
https://www.linkedin.com/in/akwasi-apori-465b5211/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.